Deeply undervalued · +49.0% margin of safety
Market outside MC distributionMarket $19.62 vs DCF $38.46 (post-governance, pre-gov $40.49). Even at the 5th-percentile Monte Carlo outcome ($31.73), intrinsic value exceeds today's price by 62%.
What it sells, where it sells
Operating segments — FY25 revenue $3.35B
Injectables is the troubled cash machine the market is fixating on, but Branded + Hikma Rx (~50% of group profit) are already re-expanding margin — the operating leverage is hiding in plain sight.
Country mix (revenue-weighted)
US is ~59% of revenue (Injectables + Rx); MENA aggregates ~32% across 10 markets — the Iran-war and stockpiling overhang lands on that second bucket, not on the core US franchise.
Background — five things to know before the case
Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.
- The Feb 26 2026 reset is the reason this is cheap. Hikma withdrew its medium-term Injectables margin target, cut 2026 revenue growth to 2-4% (vs 5.6% consensus), and guided Injectables margin 35.3% (2024) → 31.0% (2025) → ~27.5% (2026). Shares dropped 16% in a day to a three-year low. April 23 the company reaffirmed the new guide — first checkpoint passed, stock +6% on the day — but the reset's narrative damage hasn't unwound.
- Bedford OH is the central operational bet. The Xellia acquisition (closed 2024) brought a US Injectables facility that won't be productive until 2028. Capex is pulled forward into 2026-27 to fund the ramp. The base case lives or dies on whether Bedford's bag/liquid/lyophilisation lines come online roughly on time — a 1-year slip is digestible, a 3-year slip flips the case.
- Family ownership runs the company and is buying cash on the bid. The Darwazah family holds 27.04% via Darhold Limited (concert party), requiring an annual Rule 9 waiver — 43.4% of independent shareholders voted against in 2024. But Said Darwazah (CEO) bought 530K shares at 1,584p (£8.4M) in Nov 2025, and Mazen bought 200K at 1,756p (£3.5M) in Aug 2025. Both prices well above today's ~1,460p. Governance haircut sits at 5% — light, because the family is paying retail.
- Two thirds of the business is already expanding margin. Branded core revenue rose +10% in 2025 with operating margin moving 24.6% → 26.4%; Hikma Rx is guided 17.3% → ~20% in 2026 (a 270bp expansion on flat revenue). Injectables compression is masking real operating leverage in the other 50% of group profit.
- The balance sheet is investment-grade and returning cash. BBB upgraded by both S&P and Fitch in 2025, $500M Eurobond refinanced cleanly, 1.6× net debt / EBITDA, 28-year progressive dividend, $250M buyback ~25% executed in eight weeks. There is no plausible distress path — the question is operational margin, not solvency.
Where we diverge from the sector
Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.
The story & the five claims
The 10-year story this DCF is built on, plus the five anchor claims that translate the story into model inputs.
The 10-year story
Hikma is a mid-teens-ROIC, three-leg generics + branded MENA pharma whose Injectables cash machine has dropped into a documented two-year margin trough — 35.3% (2024) → 31.0% (2025) → ~27.5% guided (2026) — and the market has marked the whole company as if the trough is permanent. The base case is that it isn't. Bedford OH comes on stream productively in 2028, Branded MENA continues compounding 7-8% on biosimilar leadership with margins expanding past 26%, and Hikma Rx's 270bp margin uplift to ~20% converts to operating leverage on flat revenue. Group margin troughs at ~19% in 2026, re-anchors to ~22% by Year 5, and holds. Revenue compounds ~4.5% to $5.2B by Year 10 — management's reaffirmed 2030 target of $5B plus one year of slippage, priced for the documented 2025 guidance miss. Terminal ROIC settles at 14% — a deliberate haircut from the 16.5% five-year average to price the maturity drift conservatively, but still 700+bp above WACC.
Two debates worth pressure-testing
- Trough is cyclical, not structural. Feb-26 reset reflects a documented two-year Injectables margin trough, not a franchise impairment. April 23 reaffirmed guidance was the first checkpoint passed. Market is pricing break, the data is pricing cycle.
- Bedford OH 2028 underwrites the re-acceleration. 2026-27 trough years (~3% blended growth) flip to 2028-30 acceleration (~9%) as Bedford bag/liquid/lyo lines come on. Y10 at $5.2B = mgmt's $5B 2030 target + 1y slippage.
- Two-thirds of the business is already expanding margin. Branded core +10% with margin 24.6 → 26.4%; Hikma Rx guided 17.3 → ~20% (+270bp on flat revenue). Injectables compression masks operating leverage already showing up in the other 50% of group profit.
- ROIC discipline + insider cash + active buyback. 5-yr avg ROIC 16.5%; Said Darwazah bought 530K shares at 1,584p (£8.4M); Mazen 200K at 1,756p (£3.5M); $250M buyback ~25% executed in 8 weeks. Family is paying cash above current $19.62.
- Governance haircut 5%, not 10-20%. Insider buying in size at materially higher prices is monetary alignment, not verbal. Lagardère/Bolloré pattern is 15-20% with minority-abuse history; Hikma has none.
- Bedford OH regulatory/operational failure. Single biggest dependency. FDA refusal to certify or 3y+ slip turns base into bear: $5B target slips to 2032, Y10 lands at $4.5B, equity collapses to the $18-22 range.
- Injectables margin sticks at 2026 trough indefinitely. 27% Injectables forever + Branded slowing to MENA-GDP. Consolidated 19% margin → equity ~$22. Management already withdrew the medium-term target — they see the risk too.
- Darhold concert party — Rule 9 dynamics. 27.04% with annual waiver required; 43.4% of independent shareholders voted against in 2024. Take-private below DCF or related-party drift is the tail. The 5% post-DCF haircut already prices a meaningful chunk of this.
- MENA geopolitical escalation. Iran-war shipping/insurance plus Gulf governments mandating 6-month stockpiling. ~$100-200M working-capital strain; FX translation drag on 32.5% of revenue.
- US generic pricing reform. IRA-style negotiation extending to generic injectables/orals lowers the Rx margin floor 200bp. Current Rx guide 17.3 → 20% would compress back.
Risks to thesis
Single biggest dependency. FDA refusal to certify or 3y+ slip turns base into bear: $5B target slips to 2032, Y10 lands at $4.5B, equity collapses to $18-22 range.
Bear scenario: 27% Injectables forever + Branded slows to MENA-GDP. Consolidated 19% margin → equity ~$22. Management already withdrew the medium-term target — they see the risk too.
27.04% with annual waiver required; 43.4% of independent shareholders voted against in 2024. Take-private below DCF or related-party drift is the tail. 5% post-DCF haircut already priced.
Iran war shipping/insurance + Gulf governments mandating 6-month stockpiling. ~$100-200M working-capital strain; FX translation on 32.5% MENA revenue.
IRA-style negotiation extending to generic injectables/orals lowers Rx margin floor 200bp. Current Rx guide 17.3 → 20% would compress back.
Engine-derived WACC 6.69% uses regression β 0.62 (5Y Yahoo/StockAnalysis). Synthetic Aa2/AA proxies BBB credit (S&P+Fitch upgraded 2025). If sector β re-asserts toward 1.17, equity falls ~$5.50/sh.
10-year forecast
Revenue + FCFF on the left axis; operating margin on the right axis.
Monte Carlo distribution
Even at the 5th-percentile outcome ($31.73), intrinsic value exceeds today's $19.62 price by 62% — the disagreement isn't whether Hikma is undervalued, but by how much.
Mean $37.28 ± $3.56 · P(intrinsic < market) = 0.0% · 1000 iterations (0 failed).
- terminal_growth (0.0420) >= risk_free_rate (0.0420); the stable-growth ceiling is the risk-free rate
Cost of capital build
| Risk-free rate | 2.73% | implied from CE − β·(ERP+CRP) |
| Mature-market ERP (assumed) | ~6.60% | 2026 global mature-market ERP |
| Levered β | 0.62 | 5Y regression override (Yahoo/StockAnalysis/Lightyear) |
| Weighted CRP | 1.67% | country mix × per-country |
| Cost of equity | 7.85% | |
| Pre-tax cost of debt | 3.56% | synth rating Aa2/AA |
| WACC | 6.69% | |
| Terminal growth | 4.20% | |
| Terminal ROIC | 14.00% |
Full year-by-year DCF
| Year | Revenue | Op mgn | EBIT | EBIT(1−t) | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | $3.50B | 20.6% | $722M | $566M | $108M | $459M | $430M |
| 2 | $3.66B | 21.0% | $767M | $602M | $112M | $489M | $430M |
| 3 | $3.82B | 21.3% | $815M | $639M | $118M | $521M | $429M |
| 4 | $3.99B | 21.7% | $865M | $678M | $123M | $555M | $429M |
| 5 | $4.17B | 22.0% | $918M | $720M | $128M | $591M | $428M |
| 6 | $4.36B | 22.0% | $959M | $746M | $134M | $612M | $413M |
| 7 | $4.56B | 22.0% | $1.00B | $772M | $140M | $632M | $396M |
| 8 | $4.76B | 22.0% | $1.05B | $800M | $146M | $654M | $379M |
| 9 | $4.98B | 22.0% | $1.09B | $829M | $153M | $676M | $361M |
| 10 | $5.20B | 22.0% | $1.14B | $858M | $160M | $698M | $342M |
Methodology & flags
FCFF DCF, 10y explicit + perpetuity. R&D capitalisation: ON · Lease capitalisation: OFF · Failure-rate adjustment: OFF · ESO subtraction: OFF.